Daré Bioscience, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DARE | VERU | SPL.AX | CELZ | VTGN | ACR.AX | |
|---|---|---|---|---|---|---|
| Market cap | 13.02M | 37.51M | 222.14M | 4.95M | 8.18M | 6.12M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.3 | -2.2 | 102.2 | -0.7 | -0.1 | — |
| Price/book | -17.9 | 1.3 | 13.9 | 0.5 | 0.3 | 3.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −63.43% | −15.63% | +37.88% | −75.95% | −95.93% | −33.33% |
| Today | +1.83% | +1.85% | +1.10% | −3.21% | +9.70% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All DARE news ›Editor’s Pick: Wild Bioscience
Nature Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In…
Daré Bioscience Launches 'CEO Corner” Video Series to Highlight the Company’s Pipeline of Women’s Health Innovations, Corporate Strategy and Opportunities
New video series featuring Founder, President and CEO Sabrina Martucci Johnson will provide investors with insights into Daré Bioscience’s growing commercial portfolio, clinical pipeline and strategic priorities Access the CEO Corner here…
More from 2 other outlets
Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly
A single device designed to replace months to years of repeat injections, with potential applications well beyond its lead contraception program VP of Product Development Liz Proos presents Friday, October 30, at 2:30 p.m. ET in Boston…
Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion
Sabrina Martucci Johnson, President and CEO, shares her perspective on the recent White House Executive Order and how Daré Bioscience’s growing commercial portfolio and clinical pipeline position the Company to address critical unmet needs…
Dare Bioscience initiated with a Buy at Ladenburg
Ladenburg initiated coverage of Dare Bioscience (DARE) with a Buy rating and $2 price target Published first on TheFly – the ultimate source f... Dare Bioscience initiated with a Buy at Ladenburg Ladenburg initiated coverage of Dare…
Understanding Trimix Strength Options for Erectile Dysfunction
Trimix is an injectable medication used to treat erectile dysfunction. It usually combines three drugs: alprostadil, papaverine, and phentolamine. Each one plays a different role in helping increase blood flow, and together they create a…
Daré Bioscience Highlights 187-Fold Lower Sildenafil Exposure In Phase 1 Study
Daré Bioscience (DARE) said clinical data from a Phase 1 study of its investigational Sildenafil Cream, 3.6%, will be presented at the Annual Fall Scientific Meeting of the Sexual Medicine Society of North America (SMSNA) in Orlando,…
Tadalafil vs Sildenafil: Timing, PK, Food & Key Differences
Those differences affect treatment timing more than the shared mechanism does. Current CIALIS labeling supports an erectile-response window extending up to 36 hours after as-needed tadalafil, whereas VIAGRA labeling uses a more discrete…
Analyzing RYTHM (NASDAQ:RYM) and Dare Bioscience (NASDAQ:DARE)
Posted by Mitch Edgeman on Oct 10th, 2026 Dare Bioscience (NASDAQ:DARE – Get Free Report) and RYTHM (NASDAQ:RYM – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two…
Daré Bioscience asks approval for up to 8.93M shares
Levi Strauss & Co. Reports Third-Quarter Results SOS Limited Reports 2026 Interim Financial Results If approved and all warrants are exercised for cash, the company would issue 8,934,345 shares and receive approximately $12.4 million…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com16
- markets.businessinsider.com10
- globenewswire.com2
- stocktitan.net2
- manilatimes.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 33 articles, not a forecast.